The growing demand for autoimmune diseases and advancement in technology is fostering market growth.
Market Size – USD 9.29 Billion in
2019, Market Growth - CAGR of 17.7%, Market Trends – Rise in
cardiovascular incidences.
The global Autologous Cell Therapy Product market is forecast to reach USD 35.64 Billion by 2027, according to a new report by Reports and Data. The primary factor driving the market is the growing incidence of chronic diseases such as cancer, autoimmune diseases, and blood cancer, among many others. The rise in the population suffering from chronic conditions is also augmenting the market growth.
The global autologous cell therapy
market is anticipated to showcase an intensely competitive atmosphere in the
following years. The principal performers in the market cooperate in joint
investments, takeovers, mergers, and benefits to gain entry into the national
market. Corporations are also setting up manufacturing units and subsidiaries
in developing nations, and this initiative is contributing to the high demand
for the market.
The inception of effective guidelines
for cell therapy manufacturing, the development of advanced genomic analysis
techniques, a vast number of research by cancer societies, and proven
effectiveness of transplants are some of the primary growth factors for the
market. Certain pharmacological and manufacturing issues and regulatory hurdles
are restricting the growth of the market. The Japanese government has
recognized autologous cell therapy and regenerative medicine as a major donor
to the country’s economic growth. This has influenced the attention of global
market players towards the Asian market, thereby fostering marketing operations
in the region.
Ask for Sample Report @ https://www.reportsanddata.com/sample-enquiry-form/3355
The COVID-19 impact:
The market for autologous cell therapy
will witness a surge in demand as biopharmaceutical innovators are in the front
line for the human response to the global COVID-19 pandemic. A remarkable
number of biotech firms are in the midst of the race to scrutinize the virus's
genome and are trying to develop a viable vaccine. These companies are
investigating the virus at an unparalleled rate, and considerable funds are
being invested in the research. The companies are in trial, and the private and
public sectors are working continuously for the development of the vaccine.
Further key findings from the report suggest
·
The global autologous cell therapy
market increased at a significant CAGR over 2019 to 2027 due to the increasing
predominance of cancer across the globe and raising funds from the government
and market performers receiving support for the products.
·
Based on Application, the cancer
segment accounted for more extensive market income share in 2019, owing to the
rise in the number of patients suffering from this disease. Cancer has rapidly
grown in the coming years.
·
According to the World Health
Organization, there were 18.1 million new cases of cancer in 2018 and 9.6
million deaths in the same year. The cancer research UK has stated that the
population suffering from cancer is expected to grow in the future. It is
predicted that there will be 27.5 million new cases each year globally by the
year 2040.
·
The Hospital emerged as the largest
segment and is estimated to generate revenue of over USD 14.26 billion by 2027.
The lucrative growth in the segment is due to the increase in the number of
pipeline projects over the past few years. As per the Cancer Research Institute
(CRI), the number of projects rose from 753 in 2018 to 1,011 in 2019.
·
North America is expected to be an
active region over the forecast period. The United States will be the major
contributor and is expected to witness high growth owing to the huge amount of
funding by the government and private firms for clinical trials. The region is
expected to exhibit a CAGR of 18.2% over the forecast period.
·
Key participants include Brainstorm
Cell Therapeutics Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Holostem Terapie
Avanzate Srl, FUJIFILM Holdings Corp., Teva Pharmaceutical Industries Ltd,
Osiris Therapeutics Inc., Sumitomo Chemical Co. Ltd., Takeda Pharmaceutical Co.
Ltd, and Vericel Corp among others.
Request a customization of the report @
https://www.reportsanddata.com/request-customization-form/3355
For the purpose of this report,
Reports and Data have segmented into the global Autologous Cell Therapy Product
market on the basis of source, end-user, application, and region:
Source Outlook (Revenue, USD Billion;
2017-2027)
·
Bone Marrow
·
Epidermis
End-User Outlook (Revenue, USD
Million; 2017-2027)
·
Hospitals
·
Ambulatory Centers
·
Research Centers
Application Outlook (Revenue, USD
Billion; 2017-2027)
·
Cancer
·
Neurodegenerative Diseases
·
Wound Healing
·
Orthopedic
·
Cardiovascular diseases
·
Autoimmune Diseases
Regional Outlook (Revenue, USD
Billion; 2017-2027)
·
North America
o
U.S
o
Canada
·
Europe
o
Germany
o
U.K
o
France
o
BENELUX
o
Rest of Europe
·
Asia Pacific
o
China
o
Japan
o
South Korea
o
Rest of APAC
·
MEA
o
Saudi Arabia
o
UAE
o
Rest of MEA
·
Latin America
o
Brazil
o
Rest of LATAM
To know more about the report @ https://www.reportsanddata.com/report-detail/autologous-cell-therapy-product-market
Key Features of the Autologous Cell Therapy
Product Report:
·
The
report encompasses Autologous Cell Therapy Product market overview along with
market share, demand and supply ratio, production and consumption patterns,
supply chain analysis, and other ley elements
·
Offers
insights into production and manufacturing value, products and services offered
in the market, and fruitful information about investment strategies
·
The
report covers an extensive analysis of the trends, drivers, restraints,
limitations, threats, and growth opportunities in the Autologous Cell Therapy
Product industry
·
SWOT
analysis and Porter’s Five Forces analysis along with feasibility analysis and
investment return analysis
·
Sophisticated
analysis of the market statistics and is represented in graphs, tables, facts,
figures, diagrams, and charts to provide a better understanding
Table of Content:
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Indicative Metrics
Chapter 4. Autologous Cell Therapy Products Market Segmentation & Impact
Analysis
4.1. Autologous Cell Therapy Products Market Material
Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1.
Development of novel drugs for treatment
4.2.2.2.
Rise in demand of drugs for cardiac and degenerative disorder
4.2.2.3.
New innovation and advancement
4.2.3. Market restraints analysis
4.2.3.1.
Fueling the demand for stem cell therapies
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Metric Space Analysis
4.8. Price trend Analysis
4.9. Customer Mapping
4.10. Covid-19 Impact Analysis
4.11. Global Recession Influence
Chapter 5. Autologous Cell Therapy
Product Market By Source Insights & Trends
Continued….
Thank
you for reading our report. Customization of the report is available based on
the client’s requirements. For more details, kindly connect with us, and our
team will ensure the report is suited to meet your requirements.
No comments:
Post a Comment